Clinical relevance of host immunity in breast cancer: from TILs to the clinic (Q38669465)

5 September 2017

Clinical relevance of host immunity in breast cancer: from TILs to the clinic (English)

1 reference

5 September 2017

1 reference

6

1 reference

5 September 2017

Sherene Loi

7

0 references

Phillip K. Darcy

object named as

Phillip K Darcy

5

0 references

Carsten Denkert

object named as

Carsten Denkert

Roberto C Salgado-Delgado

3

0 references

2

object named as

Roberto Salgado

1 reference

5 September 2017

Peter Savas

1

1 reference

5 September 2017

Christos Sotiriou

4

1 reference

5 September 2017

language of work or name

English

0 references

publication date

15 December 2015

1 reference

Nature Reviews Clinical Oncology

5 September 2017

1 reference

5 September 2017

13

1 reference

5 September 2017

4

1 reference

5 September 2017

228-241

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2015.215

5 September 2017

0 references

cites work

Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC Class I and II expression in breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Immune cell quantitation in normal breast tissue lobules with and without lobulitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Leukocyte composition of human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin C as a Compatible Prognostic Marker in Human Solid Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

CD4⁺ follicular helper T cell infiltration predicts breast cancer survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Host Antitumor Immunity Plays a Role in the Survival of Patients With Newly Diagnosed Triple-Negative Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

An international Ki67 reproducibility study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

New insights into the development of lymphoid tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Molecular and genetic properties of tumors associated with local immune cytolytic activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Use of archived specimens in evaluation of prognostic and predictive biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Calreticulin exposure dictates the immunogenicity of cancer cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Regulation of epithelial-mesenchymal transition through SUMOylation of transcription factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Bias towards large genes in autism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Comprehensive molecular portraits of human breast tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Clonal expansion of T cells: a cytotoxic T-cell response in vivo that involves precursor cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Clonal expansion of human T lymphocytes initiated by dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Specific recruitment of γδ regulatory T cells in human breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Immunological aspects of cancer chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Enhancement of antitumor immunity by CTLA-4 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Nivolumab in previously untreated melanoma without BRAF mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Nivolumab plus ipilimumab in advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

OX40 costimulation turns off Foxp3+ Tregs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

OX40 is a potent immune-stimulating target in late-stage cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Immunity, inflammation and cancer: a leading role for adenosine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Immune Checkpoint Blockade in Cancer Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

PD-1 blockade induces responses by inhibiting adaptive immune resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Programmed death ligand-1 expression in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

The future of immune checkpoint therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

T cell exclusion, immune privilege, and the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.215

Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses

31 March 2020

1 reference

12 December 2020

CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion

1 reference

12 December 2020

Postnatal mammary gland development requires macrophages and eosinophils

1 reference

12 December 2020

LIFE EXPECTANCY FOLLOWING RADICAL AMPUTATION FOR CARCINOMA OF THE BREAST: A CLINICAL AND PATHOLOGIC STUDY OF 218 CASES

1 reference

12 December 2020

Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer

1 reference

12 December 2020

Clonal evolution in breast cancer revealed by single nucleus genome sequencing.

1 reference

12 December 2020

Characterization of Lymphocytes Infiltrating Human Breast Cancer, Specific Immune Reactivity Detected by Measuring Cytokine Secretion

1 reference

12 December 2020

Ultrastructure of IL2-stimulated Tumor-infiltrating Lymphocytes Showing Cytolytic Activity Against Tumor Cells

1 reference

12 December 2020

Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy

1 reference

12 December 2020

Flow cytometry: principles and clinical applications in hematology

1 reference

12 December 2020

T-lymphocyte subsets in primary lung cancer

1 reference

12 December 2020

Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation

1 reference

12 December 2020

10.1038/NRCLINONC.2015.215

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

0 references

1 reference